Skip to Content
Global News Select

Bristol-Myers Squibb 1Q Revenue, Profit Land Below Expectations

By Matt Grossman


Bristol-Myers Squibb Co. Thursday posted first-quarter revenue growth and a better earnings result than a year ago, though its sales and adjusted-profit figures came in below analysts' expectations.

The New York City-based pharmaceutical company logged earnings of 89 cents a share, compared with a loss of 34 cents a share in the same three-month period a year earlier. The company's total net earnings were $2.02 billion, compared with a loss of $775 million a year ago.

On an adjusted basis, Bristol-Myers's earnings were $1.74 a share. Analysts polled by FactSet had forecast adjusted earnings of $1.81 a share.

Revenue grew to $11.07 billion, from $10.78 billion in the prior-year period. Analysts were expecting revenue of $11.13 billion. The revenue growth was driven by sales of drugs such as Revlimid and Eliquis, partially offset by declines from Opdivo and Sprycel.

Marketing, selling and administrative expenses grew by 4% to $1.67 billion amid higher advertising and promotion expenses. Research and development spending dropped by 6% to $2.23 billion.

Bristol-Myers maintained its previously issued guidance for full-year adjusted earnings of $7.35 to $7.55 a share, forecasting world-wide revenue growth in the high single digits. Analysts surveyed by FactSet have been forecasting full-year adjusted earnings of $7.48 a share, on revenue of $46.29 billion.


Write to Matt Grossman at


(END) Dow Jones Newswires

April 29, 2021 07:35 ET (11:35 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.